Clinical Trial

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Study acronym: FLOWERS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2024 (before its estimated April 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy and safety of osimertinib with or without savolitinib as first-line therapy in patients with de novo MET positive, EGFR-mutant advanced NSCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-12-06; most recent amendment 2024-02-07.
Status change: Recruiting → Active, Not Recruiting 2024-02-07
Status change: Not Yet Recruiting → Recruiting 2023-09-23
Trial Details
NCT Number NCT05163249
Lead Sponsor Guangdong Association of Clinical Trials
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 44 participants
Start Date 2022-05-31
Primary Completion 2024-04 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2024-02-09